US Bancorp DE Has $1.82 Million Stock Holdings in Genmab A/S Sponsored ADR $GMAB

Key Points

• US Bancorp DE decreased its holdings in Genmab A/S by 18.0% during the 2nd quarter, now owning 88,158 shares valued at approximately $1.82 million.
• Several institutional investors significantly increased their stakes in Genmab A/S, with Headlands Technologies LLC raising its position by 1,525.0% in the 1st quarter.
• Wall Street analysts have shown increased confidence in Genmab A/S, with Guggenheim upgrading the stock from "neutral" to a "buy" rating and setting a price objective of $43.00.

US Bancorp DE decreased its position in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 18.0% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 88,158 shares of the company's stock after selling 19,395 shares during the quarter. US Bancorp DE's holdings in Genmab A/S were worth $1,821,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Headlands Technologies LLC raised its position in shares of Genmab A/S by 1,525.0% during the 1st quarter. Headlands Technologies LLC now owns 1,560 shares of the company's stock valued at $31,000 after acquiring an additional 1,464 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its position in shares of Genmab A/S by 124.3% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company's stock valued at $38,000 after acquiring an additional 1,070 shares during the last quarter. Parallel Advisors LLC raised its position in shares of Genmab A/S by 377.5% during the 2nd quarter. Parallel Advisors LLC now owns 3,720 shares of the company's stock valued at $77,000 after acquiring an additional 2,941 shares during the last quarter. Brooklyn Investment Group raised its position in shares of Genmab A/S by 729.3% during the 1st quarter. Brooklyn Investment Group now owns 4,246 shares of the company's stock valued at $83,000 after acquiring an additional 3,734 shares during the last quarter. Finally, Advisors Preferred LLC bought a new stake in shares of Genmab A/S during the 1st quarter valued at $84,000. Institutional investors and hedge funds own 7.07% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on GMAB. Guggenheim upgraded shares of Genmab A/S from a "neutral" rating to a "buy" rating and set a $43.00 price objective for the company in a research report on Tuesday, September 23rd. Wall Street Zen upgraded shares of Genmab A/S from a "buy" rating to a "strong-buy" rating in a research note on Friday, September 26th. HC Wainwright reissued a "buy" rating and issued a $40.00 price target on shares of Genmab A/S in a report on Wednesday. Zacks Research raised shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, October 2nd. Finally, Weiss Ratings reissued a "hold (c)" rating on shares of Genmab A/S in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Genmab A/S currently has an average rating of "Moderate Buy" and an average target price of $40.80.

Genmab A/S Price Performance

NASDAQ:GMAB opened at $32.72 on Thursday. Genmab A/S Sponsored ADR has a one year low of $17.24 and a one year high of $33.63. The company has a market cap of $21.01 billion, a PE ratio of 16.44, a PEG ratio of 1.85 and a beta of 0.98. The firm has a 50-day moving average of $27.51 and a 200-day moving average of $23.13.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, beating analysts' consensus estimates of $0.39 by $0.15. The firm had revenue of $925.00 million for the quarter, compared to analysts' expectations of $5.77 billion. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. Genmab A/S has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.